BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12469783)

  • 1. The FDA guidelines for the treatment of psoriasis using cyclosporine A: are they adequate?
    Zackheim HS
    Cutis; 2002 Nov; 70(5):288-90. PubMed ID: 12469783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclosporine in the treatment of psoriasis.
    Gulliver WP
    Cutis; 2000 Nov; 66(5):365-9. PubMed ID: 11107522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of malignancy associated with cyclosporin use in psoriasis.
    Paul C; Hornig F
    Dermatology; 1999; 198(3):320-1. PubMed ID: 10419287
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of psoriasis. Part 2. Systemic therapies.
    Lebwohl M; Ali S
    J Am Acad Dermatol; 2001 Nov; 45(5):649-61; quiz 662-4. PubMed ID: 11606913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experience with the use of cyclosporin A in psoriasis. Results of a retrospective study.
    Ojeda R; Sánchez Regaña M; Massana J; Oliete R; Umbert P
    J Dermatolog Treat; 2005; 16(4):238-41. PubMed ID: 16249146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
    Alwawi EA; Krulig E; Gordon KB
    Dermatol Ther; 2009; 22(5):431-40. PubMed ID: 19845720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric psoriasis: updates in biologic therapies.
    Sukhatme SV; Gottlieb AB
    Dermatol Ther; 2009; 22(1):34-9. PubMed ID: 19222515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined treatment with low-dose cyclosporine and calcipotriol/betamethasone dipropionate ointment for moderate-to-severe plaque psoriasis: a randomized controlled open-label study.
    Vena GA; Galluccio A; Pezza M; Vestita M; Cassano N
    J Dermatolog Treat; 2012 Aug; 23(4):255-60. PubMed ID: 21756153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporine in psoriasis: comparison of a 25-year real-world Italian experience to current European guidelines.
    Altomare G; Ayala F; Bardazzi F; Bellia G; Chimenti S; Colombo D; Flori ML; Girolomoni G; Micali G; Parodi A; Peris K; Vena GA
    G Ital Dermatol Venereol; 2016 Aug; 151(4):432-5. PubMed ID: 25786483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of psoriasis with cyclosporine in patients with hepatitis C infection: risk or opportunity?
    Di Lernia V; Albertini G
    J Am Acad Dermatol; 2010 Aug; 63(2):342-3. PubMed ID: 20633803
    [No Abstract]   [Full Text] [Related]  

  • 11. Additive effects of calcipotriol and cyclosporine A: from in vitro experiments to in vivo applications in the treatment of severe psoriasis.
    Bagot M; Grossman R; Pamphile R; Binderup L; Charue D; Revuz J; Dubertret L
    C R Acad Sci III; 1994 Mar; 317(3):282-6. PubMed ID: 7994616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis.
    Heydendael VM; Spuls PI; Opmeer BC; de Borgie CA; Reitsma JB; Goldschmidt WF; Bossuyt PM; Bos JD; de Rie MA
    N Engl J Med; 2003 Aug; 349(7):658-65. PubMed ID: 12917302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real world experience using Ciclosporin in psoriasis: Efficacy and toxicity in the Australasian Psoriasis Registry.
    Berry W; Daniel BS; Baker C; Foley P
    Australas J Dermatol; 2020 Nov; 61(4):380-382. PubMed ID: 32367517
    [No Abstract]   [Full Text] [Related]  

  • 14. Cyclosporine in the treatment of dermatologic disease: an update.
    Lim KK; Su WP; Schroeter AL; Sabers CJ; Abraham RT; Pittelkow MR
    Mayo Clin Proc; 1996 Dec; 71(12):1182-91. PubMed ID: 8945493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A boxed warning for inadequate psoriasis treatment.
    Kagha KC; Blauvelt A; Anderson KL; Leonardi CL; Feldman SR
    Cutis; 2016 Sep; 98(3):206-207. PubMed ID: 27814414
    [No Abstract]   [Full Text] [Related]  

  • 16. Coexistence of adult T-cell leukaemia /lymphoma and psoriasis treated with cyclosporine.
    Koga M; Koga K; Isitsuka K; Imafuku S; Nakayama J
    Eur J Dermatol; 2012; 22(2):275-6. PubMed ID: 22266509
    [No Abstract]   [Full Text] [Related]  

  • 17. Cyclosporine in severe psoriasis. Results of a meta-analysis in 579 patients.
    Faerber L; Braeutigam M; Weidinger G; Mrowietz U; Christophers E; Schulze HJ; Mahrle G; Meffert H; Drechsler S
    Am J Clin Dermatol; 2001; 2(1):41-7. PubMed ID: 11702620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized controlled trial of methotrexate and cyclosporine in the treatment of psoriasis.
    Bigby M
    Arch Dermatol; 2004 Mar; 140(3):347-8. PubMed ID: 15023778
    [No Abstract]   [Full Text] [Related]  

  • 19. Methotrexate in the treatment of psoriasis.
    Bright RD
    Cutis; 1999 Nov; 64(5):332-4. PubMed ID: 10582158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities.
    Balasubramaniam P; Stevenson O; Berth-Jones J
    Br J Dermatol; 2004 Apr; 150(4):741-6. PubMed ID: 15099371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.